Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
718.36
-4.44 (-0.61%)
At close: Dec 5, 2025, 4:00 PM EST
721.00
+2.64 (0.37%)
After-hours: Dec 5, 2025, 7:45 PM EST
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
$943,188
Profits / Employee
$303,058
Market Cap
73.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
| Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
| Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
| Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
| Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
| Dec 31, 2019 | 8,100 | 700 | 9.46% |
| Dec 31, 2018 | 7,400 | 1,200 | 19.35% |
| Dec 31, 2017 | 6,200 | 800 | 14.81% |
| Dec 31, 2016 | 5,400 | 1,100 | 25.58% |
| Dec 31, 2015 | 4,300 | 1,375 | 47.01% |
| Dec 31, 2014 | 2,925 | 585 | 25.00% |
| Dec 31, 2013 | 2,340 | 390 | 20.00% |
| Dec 31, 2012 | 1,950 | 246 | 14.44% |
| Dec 31, 2011 | 1,704 | 309 | 22.15% |
| Dec 31, 2010 | 1,395 | 366 | 35.57% |
| Dec 31, 2009 | 1,029 | 110 | 11.97% |
| Dec 31, 2008 | 919 | 237 | 34.75% |
| Dec 31, 2007 | 682 | 109 | 19.02% |
| Dec 31, 2006 | 573 | -15 | -2.55% |
| Dec 31, 2005 | 588 | -142 | -19.45% |
| Dec 31, 2004 | 730 | 86 | 13.35% |
| Dec 31, 2003 | 644 | -25 | -3.74% |
| Dec 31, 2002 | 669 | 94 | 16.35% |
| Dec 31, 2001 | 575 | 84 | 17.11% |
| Dec 31, 2000 | 491 | 54 | 12.36% |
| Dec 31, 1999 | 437 | 66 | 17.79% |
| Dec 31, 1998 | 371 | 101 | 37.41% |
| Dec 31, 1997 | 270 | 27 | 11.11% |
| Dec 31, 1996 | 243 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
REGN News
- 2 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 5 days ago - Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? - The Motley Fool
- 11 days ago - Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 11 days ago - Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria - GlobeNewsWire
- 11 days ago - 1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month - The Motley Fool
- 14 days ago - This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead - Investopedia